Nisoldipine



Indications and Reactions:

Role Indications Reactions
Primary
Hypertension 39.1%
Drug Use For Unknown Indication 30.4%
Abdominal Pain 8.7%
Blood Pressure Increased 8.7%
Blood Pressure 4.3%
Hypothyroidism 4.3%
Insomnia 4.3%
Increased Upper Airway Secretion 11.8%
Liver Disorder 11.8%
Rash 11.8%
Blood Pressure Increased 5.9%
Cough 5.9%
Dry Mouth 5.9%
Dry Skin 5.9%
Fatigue 5.9%
Furuncle 5.9%
Lip Swelling 5.9%
Malaise 5.9%
Oropharyngeal Pain 5.9%
Pruritus 5.9%
Small Bowel Angioedema 5.9%
Secondary
Product Used For Unknown Indication 49.6%
Completed Suicide 29.6%
Hypertension 10.4%
Abdominal Pain 1.7%
Acute Myeloid Leukaemia 1.7%
Drug Use For Unknown Indication 1.7%
Blood Cholesterol Decreased 0.9%
Blood Pressure 0.9%
Cardiac Disorder 0.9%
Crohn's Disease 0.9%
Heart Rate 0.9%
Small Bowel Angioedema 0.9%
Completed Suicide 35.0%
Small Bowel Angioedema 22.5%
Increased Upper Airway Secretion 10.0%
Tachycardia 7.5%
Death 2.5%
Fatigue 2.5%
Gastric Ulcer 2.5%
Headache 2.5%
Intentional Drug Misuse 2.5%
Liver Disorder 2.5%
Multiple Drug Overdose Intentional 2.5%
Staphylococcal Sepsis 2.5%
Torsade De Pointes 2.5%
Toxicity To Various Agents 2.5%
Concomitant
Drug Use For Unknown Indication 33.5%
Hypertension 11.3%
Product Used For Unknown Indication 7.4%
Multiple Myeloma 5.6%
Blood Pressure 4.3%
Rheumatoid Arthritis 4.3%
Cervix Carcinoma 4.1%
Asthma 3.8%
Pain 3.3%
Blood Cholesterol Increased 2.6%
Hyperlipidaemia 2.6%
Coronary Artery Disease 2.3%
Nausea 2.3%
Atrial Fibrillation 2.0%
Type 2 Diabetes Mellitus 2.0%
Arthritis 1.8%
Cardiac Disorder 1.8%
Vitamin Supplementation 1.8%
Diabetes Mellitus 1.5%
Hyperuricaemia 1.5%
Small Intestinal Obstruction 8.5%
Wound Drainage 8.5%
Cutaneous Lupus Erythematosus 6.8%
Death 6.8%
Myocardial Infarction 6.8%
Pruritus 6.8%
Skin Burning Sensation 6.8%
Hypertensive Crisis 5.1%
Nausea 5.1%
Red Blood Cell Count Decreased 5.1%
Drug Interaction 3.4%
Flushing 3.4%
Hypoaesthesia 3.4%
Off Label Use 3.4%
Pyrexia 3.4%
Rash 3.4%
Tremor 3.4%
Visual Field Defect 3.4%
Vomiting 3.4%
Weight Decreased 3.4%